Background: CYP2D6 and CYP2C19 are cytochrome P450 enzymes involved in the metabolism of many medications from multiple therapeutic classes. The genes encoding them, CYP2D6 and CYP2C19, have multiple functional variants that have been associated with different levels of enzyme activity. There is evidence that methodology for identifying such variants ("genotyping") effectively and efficiently could lead to substantial health care costs savings. There are various genotyping technologies available;
Introduction
CYP2D6 and CYP2C19 are cytochrome P450 enzymes involved in hepatic phase I reactions that alter the hydrophobicity and reactivity of substrates. Substrates for CYP2D6 include at least 25% of commonly prescribed medications from a variety of classes, including antidepressants (e.g., venlafaxine, citalopram, fluoxetine, paroxetine, amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, trimipramine,) antipsychotics (e.g., aripiprazole, risperidone, haloperidol, zuclopenthixol, and pimozide), antiarrhythmics (e.g., flecainide and propafenone), beta-blockers (e.g., metoprolol and propranolol), opioids (e.g., codeine), antiemetics (e.g., metoclopramide and ondansetron), antitussives (e.g., dextromethorphan) and anticancer agents such as the hormonal modulator tamoxifen. [1] [2] [3] [4] Substrates for CYP2C19 include proton pump inhibitors (omeprazole and pantoprazole), the antithrombotic clopidogrel, antidepressants (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, moclobemide, imipramine, amitriptyline, clomipramine), antipsychotics (e.g., clozapine and olanzapine), anxiolytics (diazepam and propranolol), the anticonvulsant phenytoin, and immunologically active agents (e.g., cyclophosphamide, nelfinavir, proguanil, and voriconazole). 4 The gene (CYP2D6) encoding the enzyme CYP2D6 is on chromosome 22q13.2 5 adjacent to two pseudogenes, CYP2D7 and CYP2D8 . 6 CYP2D7 is highly homologous with CYP2D6. 6 This arrangement is susceptible to unequal crossover events in meiosis. For example, CYP2D6 pairs with CYP2D7 or part thereof, resulting in a deletion of the CYP2D6 gene on one chromatid and an extra copy of CYP2D6 on the other, or hybrid genes containing both CYP2D6 and CYP2D7 sequences. These structural variants have been historically challenging to detect by many different types of genotyping techniques. In addition, the region is one of the most variable areas of the human genome, with over 100 different haplotypes or "star alleles" (defined by particular genetic variants or combinations thereof on the same chromosome) having been identified and catalogued. 7, 8 Moreover, new variants continue to be discovered.
It is therefore hardly surprising that genotyping of CYP2D6 for treatment optimization is not being routinely provided in clinical settings, despite the presence of guidelines indicating potential clinical utility. [9] [10] [11] The CYP2C19 gene encoding the CYP2C19 enzyme is likewise located at chromosome 10q23.33 together with other similar genes, namely CYP2C18 (not expressed at the protein level), CYP2C9, and CYP2C8. [12] [13] [14] While structural variants of CYP2C19 have recently been identified, 15 the more commonly studied "star allele" variants result from single base changes in the DNA sequence (single nucleotide variants or SNVs); more than 30 different variants in CYP2C19 have been catalogued to date. 16 Each CYP2D6 or CYP2C19 haplotype or "star allele" is associated with different levels of enzyme activity, ranging from poor metabolizer (PM) alleles, which give rise to no functional enzyme; to intermediate metabolizer (IM) alleles, which are associated with an enzyme with reduced metabolic activity; to ultrarapid metabolizer alleles (UMs), associated with increased activity. 4 In between the IM and UM activities are alleles of normal metabolizer (NM) activity. The CYP2D6 and CYP2C19 enzyme activity groups vary markedly by ethnic group. CYP2D6 UMs have been found at a frequency of 0.9 -4% in Whites and at higher frequency in Sub-Saharan Africa; CYP2D6 IMs are relatively common in East Asia and in Blacks; and CYP2D6 PMs are relatively common in Caucasians at 7% and rare in East Asians at 1%. 1 The frequency of CYP2C19 PMs is 2-5% in Caucasians, 2% in Saudi Arabians, 4% in Zimbabweans, 5% in Ethiopians, 13% in Koreans, 15-17% in Chinese, 21% in Indians, and 18-23% in Japanese. 1, 4 There is evidence that genotyping for CYP2D6 and CYP2C19 would reduce the number of adverse drug reactions (ADRs) to medications metabolized by these enzymes. For example, Pirmohamed et al. (2004) 17 found that antidepressants were the leading mental health class of medication and fifth leading medication class overall of ADR-related general hospital admissions. Methodology for genotyping these genes effectively and efficiently could therefore lead to substantial health care costs savings. The first step in introducing a new genetic test to a clinical genetics laboratory is establishing analytical validity. Our aim was to contribute to this step by cross-validating multiple technologies for genotyping CYP2D6 and CYP2C19 against each other and providing automated variant to "star allele" translation.
Methods
Ninety-six DNA samples originating from venous blood samples were selected from those previously genotyped for CYP2D6 and CYP2C19 using the AmpliChip CYP450 supplemented by a TaqMan assay C_469857_10 for CYP2C19*17 as part of the Genome-based therapeutic drugs for depression (GENDEP) study 18 . Participants were all of self-reported White European ancestry. The AmpliChip identified 32 Samples were quantified using fluorimetry-based methods (Qubit or Quantifluor). TaqMan copy number assays for CYP2D6 (assay IDs: Hs04083572_cn, and Hs00010001_cn for intron 2, and exon 9 respectively; Thermo Fisher Scientific) were run according to the manufacturer's protocol on a ViiA7
Real-Time PCR System (Thermo Fisher Scientific, Aitchison laboratory), with a minor modification (TaqMan Universal Mastermix II no UNG was used instead of Genotyping MasterMix). The assays are specific for intron 2 and exon 9 in CYP2D6, with DNA not being amplified if the relevant region is CYP2D7 sequence. Assays were run in quadruplicate with internal calibrators of known CYP2D6 copy number. Data were analysed using Copy-Caller software version 2.1 (Thermo Fisher Scientific) with internal calibrators of known CYP2D6 copy number according to the manufacturer's instructions (using a confidence level of 95% and z-score value of less than 1.75).
Samples for which the TaqMan CNV call across the two probes were not equal were analysed with a third probe (assay ID Hs04502391_cn for CYP2D6 intron 6). These samples and those with a unique combination CYP2D6 and CYP2C19 genotypes by the AmpliChip CYP450 and TaqMan CYP2C19*17 assays, or no reference sample for that genotypic combination available at the time of selection (June 2019), or no call on the AmpliChip CYP450 were then taken forward for further analysis. The following genotyping techniques were employed: PharmacoScan (Thermo Fisher Scientific), Ion S5 AmpliSeq Pharmacogenomics Panel (Thermo Fisher Scientific), and TaqMan Drug Metabolism Genotyping Assays (Thermo Fisher Scientific). Samples were selected on the basis of the above data for the generation of specific long amplicons by polymerase chain reaction (known as XL-PCR) for the detection of specific gene CYP2D6 deletion, duplication and conversion events. [19] [20] [21] Products of XL-PCRs for conversion events were In addition, a TaqMan assay for CYP2C19*2 (assay ID C_25986767_70) was used as a further validation test for this SNV.
Ion S5 AmpliSeq Pharmacogenomics Panel
Genotyping using the Ion S5 AmpliSeq Pharmacogenomics Panel (Thermo Fisher Scientific) was conducted according to the manufacturer's instructions using an Ion Chef instrument (Thermo Fisher Scientific, Waltham MA). Short stretches of genomic DNA were sequenced, including regions of CYP2D6 designed to detect gene deletion, duplication and conversion (CYP2D6-2D7 hybrid) events. In brief, library preparation was conducted using the Ion AmpliSeq Library Kit Plus (genomic DNA was subjected to a multiplex PCR using a pool of primer pairs). The resulting amplicons were then partially digested and ligated to barcode adaptors (Ion Express barcode adaptors 1-96 kit, Thermo Fisher Scientific), which were then purified using a magnetic bead technology (AMPure XP Reagent, Agencourt). Library quantitation was carried out by quantitative PCR using the Ion Library TaqMan Quantitation Kit (Thermo Fisher Scientific) and was followed by normalisation of library concentration to 40 pM. Two chips were then loaded, containing libraries 1-48 and 49-96 respectively. Following sequencing, data were accessed remotely using the GeneStudio Data Analysis software (Thermo Fisher Scientific). Ion S5 sequencing generated an average of 109,454 reads per sample (mean read length 142.5 bp), with two samples failing quality control (in a manner indicating likely insufficient template: mapped read numbers of 18 and 51). Variant calling by the Ion Torrent Variant Caller version 5.10.1.19 (Thermo Fisher Scientific) generated three text files: one with the genotype at each SNV (including 20 CYP2D6 variants and 11 CYP2C19 variants), one for the CYP2D6 exon 9 CNV output, and one for the CYP2D6 gene level CNV data (based on sequence across two regions in intron 2 to exon 4, one spanning exon4-intron3-exon3 and one in the exon-3-intron2 region) (genomic locations 42524932-42525095 and 42525131-42525245, GRCh38/hg38 assembly). Translator files were created to derive CYP2D6 and CYP2C19 alleles from the SNV and CNV data using the AlleleTyper software (Thermo Fisher Scientific).
These translator files are available at https://flintbox.com/public/project/61820/.
PharmacoScan
PharmacoScan is an array-based technology in which the sample DNA is hybridized to short lengths of DNA pre-bound to a "gene chip;" this assay was run at Neogen Genomics (Nebraska, USA). Genomic DNA was amplified (including preferential amplification of CYP2D6 and CYP2C19), with the amplicons then being fragmented, labelled, and hybridized to a PharmacoScan Array (Thermo Fisher Scientific).
Arrays stained with a fluorescent antibody were scanned on a GeneTitan Multi-Channel Instrument (Thermo Fisher Scientific). The resultant data including more than 100 variants in CYP2D6 and 60 variants in CYP2C19 were analysed using the Axiom Analysis Suite 4.0.3.3 (Thermo Fisher Scientific).
Updates were made to manufacturer's allele translation file for CYP2D6 in order to improve the range of allele discrimination. CNV calls were provided by probes for exon 9 of CYP2D6 as well as for the 5' and 3' flanking regions as described. 22 
Long-range PCR assays with characterisation of resultant amplicons
Haplotype assignment for samples with a call of three across the TaqMan or Pharmacoscan CNV probes was conducted by XL-PCR as described to generate an amplicon specific for the duplicated gene 20 followed by clean up of the resultant amplicons GenElute PCR Clean-Up Kit (Sigma Aldrich) and the use of TaqMan Drug Metabolising assays specific for the alleles found in samples of heterozygous CYP2D6XN genotype by at least one platform (*2, *3, *4, *6, *10, *35 and *41, TaqMan assay IDs C_27102425_10, C_32407232_50, C_27102431_D0, C_32407243_20, C__11484460_40, C_27102444_F0, and C_34816116_20 respectively). Samples were run in duplicate on a ViiA7 Real-Time PCR System (Thermo Fisher Scientific), using automated genotype calling after visual inspection, outlier exclusion, and manual adjustment of C T threshold settings. Data were exported using an automated method available from the authors at request.
Samples with unequal calls across the TaqMan, PharmacoScan or Ion S5 CNV probes were subjected to XL-PCR assays to generate products specific for CYP2D6-2D7 or CYP2D7-2D6 hybrids (amplicons E and G) as described, 21 with minor modifications. The resultant amplicons were then run on the Agena
MassARRAYand the data compared with that arising from running the genomic DNA from the same samples through the Agena MassARRAY.
The Agena MassARRAY
The Agena MassARRAY (Agena Bioscience, San Diego, CA) uses matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) mass spectrometry technology for resolving oligonucleotides. We used the Veridose Core plus CYP2D6 copy number variant (CNV) panel for 18
CYP2D6 variants plus gene deletion, duplication and CYP2D6-2D7 conversion events and 9 CYP2C19
variants. In addition, we ran five custom assays for CYP2D6: *25, *35, *40, *42, and *44. Genomic DNA was subjected to PCR followed by single-base extension with the extension products then being dispensed onto a SpectroCHIP Array and detected via mass spectrometry as described (Gaedigk et al., 2019) with star alleles being assigned using Typer Analyzer software version v4.1.83 (Agena Bioscience).
Results

CYP2C19
There was a mean of 1112.19 mapped reads per CYP2C19 variant in the Ion S5 data. Data for CYP2C19 are shown in Table 1 . The CYP2C19 Ion S5 data were concordant with the prior genotypic information For the CYP2C19*2, the Ion S5, PharmascoScan and TaqMan data were 100% concordant.
CYP2D6
While the Ion S5 SNV data were of high quality (mean 1,111.13 mapped reads per variant), the CNV data had a relatively high proportion of no calls (4.21 and 18.95 for the gene level and exon 9 CNV probes respectively). The CNV data from PharmacoScan together with the prior TaqMan CNV data were therefore used as a basis for grouping samples for further analysis. Comparative genotypic and CNV data across the three platforms are shown in Table 2 . Table 1 ). For samples with a CNV call of one across the probes, there was 100% concordance between the two platforms ( Table 2) . For samples with a CNV call of three across the TaqMan or Pharmacoscan CNV probes, the concordance was 76.5% (13/17) ( Table 3 ).
The four non-concordant samples had an undetected call for the Ion S5 exon 9 CNV probe, with a resultant likely erroneous putative assignment of hybrid allele containing genotypes in three of those ( 23 ).
Concordance was less for samples with unequal calls across the TaqMan or Pharmacoscan or Ion S5 CNV probes, consistent with hybrids (formed from part of the CYP2D6 gene and part of its adjacent CYP2D7 gene).
Comparing the above with the prior data from AmpliChip revealed the following: For the CNV call two samples ( Supplementary Table S1 ), the PharmacoScan-AmpliChip concordance was 77.1%, the Ion Figure 1 and Thermo Fisher, personal communication). The relative locations of the three TaqMan probes and the Pharmacoscan 5' flanking and 3' flanking probes have been previously described ( 22 , Figure 1 ). The remaining Ion S5 CYP2D6 "gene level" CYP2D6 CNV call is integrated from probes in the intron 2 to exon 4 region as described above. The most likely consensus genotype for this sample is therefore CYP2D6*1/*4.
While the AmpliChip provided haplotyping of the CYP2D6XN (i.e., assignment to one or other of the two chromosomes), neither PharmacoScan nor Ion S5 attempt to do that. CYP2D6XN positive samples comprised samples with the following alleles: CYP2D6*1, *2, *3, *4, *6, and *41. Haplotype assignment may be conducted by XL-PCR followed by product clean-up and the use of relevant TaqMan assays as above described.
Sixteen samples had an unequal call across at least two out of three CNV probesets (TaqMan or PharmacoScan or Ion S5); for eight of these, the CNV pattern was consistent with a CYP2D7-2D6 hybrid, and for eight with a CYP2D6-2D7 hybrid. For all of the CYP2D6-2D7 hybrids, the pattern was consistent with an extra CYP2D6 gene, either on the same allele as the hybrid gene (in "cis"), or on the other chromosome 22 (in "trans"). This was also the case for four of the CYP2D7-2D6 hybrids. The expected XL-PCR amplicons were generated for all of these 16 samples. For an additional five samples with putative hybrids owing to unequal call across the Ion S5 CNV probes but equal call across the PharmacoScan and TaqMan CNV probes, XL-PCR products consistent with hybrid types predicted by the Ion S5 CNV pattern could not be reliably generated. As the Ion S5 CNV probes have at present a relatively high failure rate and would therefore appear to be less reliable than the CNV probes of the other platforms, we conclude that the Ion S5 data were misleading, and in fact these samples do not represent hybrids. One sample was genotyped as CYP2D6*1/*2 by all platforms and copy number 2 on all CNV probes apart from the TaqMan intron 2 CNV probe, which we conclude was an outlier in the data.
Genotypes for the hybrids were predicted using the combination of available data and the samples may be further analysed by subjecting the XL-PCR amplicons to genotyping using, for example, the Agena
MassARRAY.
Discussion
For CYP2C19, the overall Ion S5-PharmacoScan functional genotype concordance was 97.8% (92/94).
Moreover, the Ion S5 and PharmacoScan CYP2C19*2 data were 100% concordant with that from a TaqMan CYP2C19*2 assay (assay ID C_25986767_70).
For CYP2D6, the IonS5 data showed a high rate of concordance with PharmacoScan solution for CYP2D6 variants over a range of alleles tested apart from the XN and hybrid variants. Despite greater allele coverage by the PharmacoScan relative to the Ion S5, for samples without complex structural variants of CYP2D6 genes, there were no genotypes that were inconsistent between the two platforms. To date it has been thought that it was not possible to employ next generation sequencing technology on genomic DNA for genotyping CYP2D6; rather, that one would have to first amplify up the whole gene and its surrounding regions and then use such technology. 22 The Ion S5 AmpliSeq Pharmacogenomics
Panel is to our knowledge the first product that uses a next generation platform to genotype CYP2D6 variants from genomic DNA. Sixty-two different CYP2D6 genotypes according to the AmpliChip CYP450 data were represented in the 96 samples analyzed herein, equating to 82.7% (65/75) of the range of AmpliChip genotypes in the GENDEP data. Alleles not represented in the prior AmpliChip data include the hybrid variants and others that are infrequent in Caucasians. 24 We have herein demonstrated the feasibility of using this technology in this manner for a substantial proportion of the variety of CYP2D6 genotypes and all of the common CYP2C19 genotypes seen in Whites. We have also developed tools to facilitate the bioinformatic interpretation of such data into "star alleles" of known function, so that enzyme activity can be deduced. Moreover, these tools could be adapted for the interpretation of data from specific variants in these genes arising from any other platform.
Both platforms were also able to call CYP2D6*5 (gene deletion) variants in a manner consistent with each other and more reliably than the AmpliChip. Given the failure to detect CYP2D6*5 reliably by the AmpliChip, the rest of available GENDEP samples were screened for CYP2D6*5 using the TaqMan intron 2 and exon 9 probes, which revealed seven samples (7/853, 0.8%) with a CNV one call consistent with the presence of a previously undetected CYP2D6*5 allele.
For the CNV call three samples (consistent with a duplicated CYP2D6 gene or XN call, specifically X2, on one chromosome), the genotype on at least one platform was consistent with an XN call, with phase assignment of the XN being possible by amplifying the duplicated gene and using the resultant amplicon as a template for TaqMan SNV genotyping. The frequency of CYP2D6XNs by TaqMan CNV analysis in GENDEP was 3.8% (33/853), consistent with prior data. 19 A focus of recent research on CYP2D6 is the hybrid alleles. 21, 25 Using TaqMan CYP2D6 CNV probes, we have identified data patterns consistent with hybrid alleles in 2%, 18/853 GENDEP samples, and presented such data. 26 Where CNV call was unequal across platforms, the particular pattern of CNV call was used to infer types of hybrid allele configurations, and hence which XL-PCR set of primers should be employed to generate templates for SNV genotyping. Our previous validation work found a 100% concordance between TaqMan and DMETPlus CYP2D6*41 genotyping and between TaqMan and PharmacoScan rs5758550 genotyping. 23, [27] [28] [29] The Luminex CYP2C19 xTAG v3 has been validated against the Motorola Life Sciences eSensor DNA detection system. 30 We propose the following methodology for genotyping for CYP2D6: use a high throughput platform (e.g., Ion S5, PharmacoScan or Agena) with automated allele translation plus TaqMan CYP2D6 CNV analysis, followed by XL-PCR for gene duplications or hybrids and using the resultant amplicons as templates for genotyping (using the same high throughput platform as used for genotyping the genomic DNA), and compare the data from the amplicons with that from genomic DNA to derive genotypes for the relevant CYP2D6 structural variants. The utilization of a greater number of CYP2D6 CNV probes by the platforms where necessary and improvements in performance of such probes where indicated should enhance the feasibility of this suggested workflow.
In addition to the complexity of the locus, another barrier that has limited CYP2D6 to date has been the cost of the genotyping technology. The cheapest way to genotype is in fact by sequencing. The most high throughput (and therefore potentially most cost-effective) sequencing methodology is NGS. And while we have developed translators specifically for use with the Ion S5, they could be adapted for other NGS platforms such as Illumina. Should an NGS provider develop a panel including not only a greater number of CYP2D6 SNVs covered than those included in the Ion S5 AmpliSeq Panel but also a greater number of more reliable CYP2D6 CNV probes and offer this at a competitive price, this could be a gamechanger: moving CYP2D6 from the position of being a locus that by virtue of its challenging complexity has been inconsistently genotyped to one for which genotyping becomes accessible and affordable.
Conclusion
The inter-platform concordance for CYP2C19 was high (94-98%). For CYP2D6, the IonS5-PharmacoScan concordance was 94% for a range of variants tested apart from those with at least one extra copy of a CYP2D6 gene or a pseudogene-gene conversion. We have also demonstrated feasibility of using a NGS platform for genotyping CYP2D6 and CYP2C19, and, moreover, that this provides adequate coverage of CYP2D6 for approximately 94% of Whites. Further, we have generated automated methods for translating NGS CYP2D6 sequencing data into CYP2D6 haplotypes (star alleles). We suggest a minimum set of assays for CYP2D6 and CYP2C19 as follows: either NGS or another relevant platform (e.g., PharmacoScan or Agena MassARRAY) in combination with specific TaqMan probes for detecting CYP2D6 copy number, with follow through of a subset of such data by XL-PCR and CYP2D6 amplicon genotyping. CYP2D6 and CYP2C19 genotyping may thereby become much more readily accessible, with potential substantial savings in health care costs and public benefit. 
